suramab, a new pharmaceutical compound with antiangiogenic effects
- Summary
- This can be seen in the patent file
- Technology Benefits
- Suramab is the brand name of a new combination of drugs made up of suramin and bevacizumab. Suramab has antiangiogenic properties that can be applied to oncological and ophthalmological diseases.
The european patent (EP 2186529 B1) was granted in March 2012.
The US patent is still pending
- Application No.
- MX2008000104
- Coverage Areas
- Great Britain, Ireland, Sweden, Denmark, The Netherland, Germany, Spain, France
- Goods and Services
- License agreement
- Patent Information
- Issued patent
- Country/Region
- Argentina
For more information, please click Here
